Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
January 6, 2003
COZAAR™ (losartan potassium)
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Losartan Potassium - LIFE Study, Merck Research Laboratories (PDF)